Thiochromenes are versatile sulfur-containing heterocyclic compounds that have received considerable interest in drug discovery because of their ability to act as crucial building blocks for synthesizing bioactive compounds. In particular, these scaffolds have found utility in the design of anticancer, anti-HIV, antioxidant, and antimicrobial agents, among others. Despite their pharmacological potential, the synthesis of these scaffolds is less explored in contrast to their oxygen-containing counterparts. This review classifies the synthetic processes into Michael addition, cycloaddition, ring-opening, coupling, cyclization and Diels-Alder reactions, and others. Reaction mechanisms, circumstances, and important instances are thoroughly discussed in each area. For instance, chiral catalysts and substrates like mercaptobenzaldehyde and cinnamaldehyde are used in Michael addition processes to achieve excellent enantioselectivity. In cycloaddition reactions, readily available substrates such as thioisatins and alkynes achieve regioselectivity and product production. Thiochromenes are also synthesized by ring-opening reactions with epoxides or aziridines. These reactions demonstrate the importance of catalysts and solvents in reaction control, particularly palladium catalysts for aryl halides and thiol coupling processes. Another major class discussed is cyclization reactions with alkynyl thiols and alkynes under regulated temperature and pressure conditions to efficiently synthesize thiochromenes. With the use of chiral substrates and catalysts, Diels-Alder processes increase yields and selectivity and enhance the variety of thiochromene compounds. This review emphasizes the versatility of thiochromenes in drug discovery and consolidates the existing literature on thiochromenes, scrutinizing the gaps and opportunities for synthesizing novel thiochromene-containing lead molecules.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1039/d4ob00690a | DOI Listing |
Biochem Pharmacol
December 2024
Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China; Zhongshan Institute for Drug Discovery, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Zhongshan, China; University of Chinese Academy of Sciences, Beijing, China. Electronic address:
With the recent approval of Resmetirom as the first drug targeting nuclear receptors for metabolic dysfunction-associated steatohepatitis (MASH), there is promising way to treat MASH-associated liver fibrosis. However, liver fibrosis can arise from various pathogenic factors, and effective treatments for fibrosis due to other causes remain elusive. The activation of hepatic stellate cells (HSCs) represents a central link in the pathogenesis of hepatic fibrosis.
View Article and Find Full Text PDFBioorg Chem
December 2024
Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, School of Pharmaceutical Engineering, Shenyang Pharmaceutical University, Shenyang 110016, PR China. Electronic address:
Enhancer of Zeste Homolog 2 (EZH2) is overexpressed in many malignancies and plays a critical role in cancer progression. Therefore, it is considered a promising target for therapeutic intervention. Although several EZH2 inhibitors have entered clinical trials, only one has received FDA approval.
View Article and Find Full Text PDFBMC Med
December 2024
Department of Non-Communicable Disease Epidemiology, Faculty of Epidemiology & Population Health, London, School of Hygiene and Tropical Medicine, London, UK.
Background: Direct oral anticoagulants (DOACs) have been reported to be associated with a higher risk of mortality compared with an older alternative, warfarin using primary care data in the United Kingdom (UK). However, other studies observed contradictory findings. We therefore aimed to investigate the association between mortality and warfarin, compared with DOACs.
View Article and Find Full Text PDFJ Control Release
December 2024
School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China; State Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China; Guangdong Provincial Key Laboratory of Chiral Molecule and Drug Discovery, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China. Electronic address:
Therapeutic challenges of chronic pulmonary infections caused by multidrug-resistant Pseudomonas aeruginosa (MDRP. aeruginosa) biofilms due to significantly enhanced antibiotic resistance. This resistance is driven by reduced outer membrane permeability, biofilm barriers, and excessive secretion of virulence factors.
View Article and Find Full Text PDFRedox Biol
December 2024
Jacqui Wood Cancer Centre, Division of Cancer Research, School of Medicine, University of Dundee, Dundee, UK; Department of Pharmacology and Molecular Sciences and Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Non-communicable chronic diseases (NCDs) are most commonly characterized by age-related loss of homeostasis and/or by cumulative exposures to environmental factors, which lead to low-grade sustained generation of reactive oxygen species (ROS), chronic inflammation and metabolic imbalance. Nuclear factor erythroid 2-like 2 (NRF2) is a basic leucine-zipper transcription factor that regulates the cellular redox homeostasis. NRF2 controls the expression of more than 250 human genes that share in their regulatory regions a cis-acting enhancer termed the antioxidant response element (ARE).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!